Can Nkarta stand out from the CAR-NK crowd?

Over the years we have written quite a bit about NK cell therapies and CAR-NKs in particular.

To date none have been approved, although there is certainly plenty of competition in this niche.

The latest company to showcase their emerging data on early clinical developments are Nkarta Therapeutics.

Here we take a look at their recent data on several fronts and offer insights based on what we know about the biology involved and where things might be headed in the future.

To continue reading our latest highlights on oncology new product development, including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by